Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
Akebia received notification from the
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat is an investigational new drug and is not approved by the
Forward Looking Statement
Statements in this press release regarding
Akebia Therapeutics® is a registered trademark of Akebia Therapeutics, Inc.
Akebia Therapeutics Contact
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-received-interim-response-from-the-fda-to-appeal-for-vadadustat-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-301751320.html